# Ozempic at a Crossroads: Regulation, Brain Science, and Market Shifts

**Navigating Ozempic: Regulatory Crackdowns, Brain Science Breakthroughs & Price Wars Explained** Ozempic is making headlines again—and this episode breaks down everything you need to know. From a major pharmacy enforcement drive in Telangana, India (43 shops issued show cause notices for illegal Ozempic and Mounjaro sales) to the FDA's proposal to phase out compounded semaglutide by 2026, regulators worldwide are tightening their grip on GLP-1 medications. We dive into eye-opening new research revealing how Ozempic may target a "hidden craving center" in the brain called the lateral septum—potentially unlocking new treatments for addiction and compulsive behavior. Plus, groundbreaking Yale research challenges everything we thought we knew about how semaglutide suppresses appetite, showing it may actually *repurpose* hunger neurons rather than simply shutting them off. On the business side, we unpack Novo Nordisk's latest earnings, the impact of generic semaglutide entering Canadian pharmacies (with prices dropping to $75/month), and how Maryland's Prescription Drug Affordability Board could save residents $164 million annually on Ozempic alone. We also examine a critical new JAMA Surgery study on whether pre-surgery Ozempic use actually improves bariatric surgery outcomes (spoiler: the data says no), and explore surprising findings on how GLP-1 users may unintentionally become less physically active as weight loss progresses. Whether you're a patient, caregiver, healthcare provider, or just following the semaglutide revolution, this episode delivers the critical updates shaping Ozempic's future—covering safety concerns, pricing shifts, emerging science, and real-world implications for millions of users. **Topics covered:** Ozempic regulation news, semaglutide pricing, GLP-1 drug safety, Ozempic brain research, weight loss drug access, Novo Nordisk earnings, generic Ozempic Canada, bariatric surgery GLP-1 outcomes, Ozempic side effects, semaglutide 2026 outlook. *Disclaimer: This podcast is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare professional before starting, stopping, or combining G Some great Deals https://amzn.to/49SJ3Qs For more check out http://www.quietplease.ai